PROFECTUS BIOSCIENCES, INC.
DNA vaccines with genetic adjuvants for HIV, combining electroporation delivery with RIG-I signaling-based immune enhancers
- Sector
- Biotech
- Headquarters
- BALTIMORE, MD
- Latest Form D
- $300K, May 2016
- Total capital
- $54.8M
- Federal grants
- $11.2M
- 12 awards · 2015–2018
- Rank in peer group#42 of 514
- Private capital raised
- $5.3M
- 2 Form D · last May 2016
- 126 months since last filing
- Federal contracts
- $38.3M
- 6 awards · Health and Human S
- Rank in Biotech#23 of 4373
- Granted patents
- 1
- 6 pending · first 2018
- Rank in peer group#186 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Optimization of an innate immune stimulating adjuvant for an HIV DNA vaccine$993K
- Federal contractHealth and Human S · Novel Vaccine Technologies And Strategies To Promote Sustained Vaccine Efficiency$322K
- Federal contractHealth and Human S · Igf::ot::igf R&d- Medical: Biomedical (applied Research/exploratory Development)$3.4M
- Federal grantHealth and Human S · Phase II · Optimization of a Therapeutic HIVSIV Multi-Antigen DNA Vaccine$838K
- Federal grantHealth and Human S · Phase I · Therapeutic Vaccine for Walnut and Pecan Allergies$241K
- Federal grantHealth and Human S · Phase II · Novel Mucosal Adjuvant for an HIV DNA Vaccine$793K
- Federal grantHealth and Human S · Phase II · Optimization of a Therapeutic HIVSIV Multi-Antigen DNA Vaccine$969K
- Private capital raisedForm D · SEC · 2nd filing$300K
- Private capital raisedForm D · SEC · 1st filing$5M
Show 11 earlier federal awards
- Federal grantHealth and Human S · Phase II · An HIV Vaccine Strategy Based on Priming with rVSV Expressing FLSC$1M
- Federal grantHealth and Human S · Phase II · Novel Mucosal Adjuvant for an HIV DNA Vaccine$734K
- Federal grantHealth and Human S · Phase I · DNA Prime / Subunit Boost Multi-Antigen Universal Influenza Vaccine$300K
- Federal contractHealth and Human S · Igf::ot::igf Production Of Pdna Vaccine Expressing Flsc$74K
- Federal grantHealth and Human S · Phase II · Optimization of a Therapeutic HIVSIV Multi-Antigen DNA Vaccine$998K
- Federal grantHealth and Human S · Phase II · Optimization of a Therapeutic HIVSIV Multi Antigen DNA Vaccine$2.8M
- Federal grantHealth and Human S · Phase II · An HIV Vaccine Strategy Based on Priming with rVSV Expressing FLSC$1M
- Federal grantHealth and Human S · Phase II · Optimization of a DNA Subunit Regimen for an HIV Vaccine$549K
- Federal contractHealth and Human S · Igf::ot::igf For Profectus Biosciences, Inc$6.5M
- Federal contractHealth and Human S · HIV-1 Vaccine Candidates Delivered By Vsv Vectors$8.8M
- Federal contractHealth and Human S · Therapeutic Immunization Against Hiv With Adjuvant-enhanced Dna And Multi-epitope Peptide Vaccines$19.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
11months
from PROFECTUS BIOSCIENCES, INC.’s first federal award to its first private round.
- First federal award · Sep 2008
- Health and Human S · $19.2M
- First Form D · Jul 2009
- $5M · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#42 · top 8%
- Granted patents#186 · top 36%
- Linked publications#50 · top 10%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alexander G. RichDirectorNamed in SEC Form D filings
- Brian AdamskyDirectorNamed in SEC Form D filings
- Donald CaldwellDirectorNamed in SEC Form D filings
- Frederick C. TecceDirectorNamed in SEC Form D filings
- Jeffrey N. MeshulamExecutive Officer, DirectorNamed in SEC Form D filings
- Jeffrey StelloExecutive OfficerNamed in SEC Form D filings
Show all 19 people
- Joseph BerardinoDirectorNamed in SEC Form D filings
- M.G. G. SarngadharanDirectorNamed in SEC Form D filings
- M.G. G. SarngaharanExecutive OfficerNamed in SEC Form D filings
- Michael K. GreenebaumDirectorNamed in SEC Form D filings
- Reinhard C. KurthDirectorNamed in SEC Form D filings
- Shawn Patrick O'BrienExecutive Officer, DirectorNamed in SEC Form D filings
- Stewart J. GreenebaumDirectorNamed in SEC Form D filings
- Terry A. LiermanDirectorNamed in SEC Form D filings
- Thomas A LynchDirectorNamed in SEC Form D filings
- Thomas G. PaeseDirectorNamed in SEC Form D filings
- Thomas G. PeaseExecutive Officer, DirectorNamed in SEC Form D filings
- Tom K. PeaseExecutive OfficerNamed in SEC Form D filings
- William A HaseltineDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 7- GrantedRecombinant Isfahan Viral VectorsUSPTOUS 9,932,564
- PendingRecombinant Isfahan Viral VectorsUSPTOApplication PCTUS2015018156
- PendingCompositions And Methods For Treating And Preventing Hepatitis C Virus InfectionUSPTOApplication PCTUS2013074627
Show all 7 patent records
- Recombinant Isfahan Viral VectorsApr 3, 2018 · US 9,932,564Granted
- Recombinant Isfahan Viral VectorsApplication PCTUS2015018156Pending
- Compositions And Methods For Treating And Preventing Hepatitis C Virus InfectionApplication PCTUS2013074627Pending
- Inhibitors Of Nf-kbApplication PCTUS2010038744Pending
- Inhibitors Of Nf-kbApplication PCTUS2010032880Pending
- Inhibitors Of Nf-kbApplication PCTUS2010028610Pending
- Compositions And Methods For Treating Viral InfectionsApplication PCTUS2008002177Pending
Recent research by its founders
- Accelerated cGMP production of near-native HIV-1 Env trimers following electroporation transfection and immunogenicity analysis20253 cites
- Development of a Stable Lyophilized Formulation of a Quadrivalent Frame-Shift Peptide Vaccine for Cancer Prevention in Lynch Syndrome20250 cites
- A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus202196 cites
Related companies, and why
- EITR BIOLOGICS, INC.Similar federal contract value in Biotech · $39.6M in contracts
- Sciome LLCSimilar federal contract value in Biotech · $39.3M in contracts
- Soligenix, IncSimilar federal contract value in Biotech · $39.1M in contracts
- Argos TherapeuticsSimilar federal contract value in Biotech · $38.2M in contracts
- APTITUDE MEDICAL SYSTEMS INCSimilar federal contract value in Biotech · $36.5M in contracts
- AMGEN INCSimilar federal contract value in Biotech · $34.9M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .